Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.83+0.10 (+3.86%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Recursion Pharmaceuticals shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Recursion Pharmaceuticals's shares outstanding was 532M at Jun 30, 2026. For fiscal 2025 it was 447M, up 63.2% from the year before. The highest annual figure on record is 447M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 447M | +63.2% |
| FY2024 | Dec 31, 2024 | 274M | +31.9% |
| FY2023 | Dec 31, 2023 | 208M | +18.4% |
| FY2022 | Dec 31, 2022 | 176M | +40.0% |
| FY2021 | Dec 31, 2021 | 125M | +475.5% |
| FY2020 | Dec 31, 2020 | 22M | +1.0% |
| FY2019 | Dec 31, 2019 | 22M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 532M | +27.6% |
| Q1 FY2026 | Mar 31, 2026 | 529M | +31.4% |
| Q4 FY2025 | Dec 31, 2025 | 522M | +55.1% |
| Q3 FY2025 | Sep 30, 2025 | 447M | +58.2% |
| Q2 FY2025 | Jun 30, 2025 | 417M | +72.3% |
| Q1 FY2025 | Mar 31, 2025 | 403M | +70.7% |
| Q4 FY2024 | Dec 31, 2024 | 336M | +51.5% |
| Q3 FY2024 | Sep 30, 2024 | 283M | +31.8% |
| Q2 FY2024 | Jun 30, 2024 | 242M | +20.2% |
| Q1 FY2024 | Mar 31, 2024 | 236M | +23.2% |
| Q4 FY2023 | Dec 31, 2023 | 222M | +19.6% |
| Q3 FY2023 | Sep 30, 2023 | 214M | +23.6% |
| Q2 FY2023 | Jun 30, 2023 | 201M | +17.0% |
| Q1 FY2023 | Mar 31, 2023 | 192M | +12.3% |
| Q4 FY2022 | Dec 31, 2022 | 186M | +9.4% |
| Q3 FY2022 | Sep 30, 2022 | 173M | +2.9% |
| Q2 FY2022 | Jun 30, 2022 | 172M | +24.5% |
| Q1 FY2022 | Mar 31, 2022 | 171M | +641.0% |
| Q4 FY2021 | Dec 31, 2021 | 170M | +671.6% |
| Q3 FY2021 | Sep 30, 2021 | 169M | +672.5% |
| Q2 FY2021 | Jun 30, 2021 | 138M | +539.0% |
| Q1 FY2021 | Mar 31, 2021 | 23M | +6.4% |
| Q4 FY2020 | Dec 31, 2020 | 22M | – |
| Q3 FY2020 | Sep 30, 2020 | 22M | – |
| Q2 FY2020 | Jun 30, 2020 | 22M | – |
| Q1 FY2020 | Mar 31, 2020 | 22M | – |
See a number that looks wrong?